JP2004510750A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2004510750A5 JP2004510750A5 JP2002532258A JP2002532258A JP2004510750A5 JP 2004510750 A5 JP2004510750 A5 JP 2004510750A5 JP 2002532258 A JP2002532258 A JP 2002532258A JP 2002532258 A JP2002532258 A JP 2002532258A JP 2004510750 A5 JP2004510750 A5 JP 2004510750A5
- Authority
- JP
- Japan
- Prior art keywords
- agonist
- ppardelta
- activator
- ppar delta
- treatment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108010015181 PPAR delta Proteins 0.000 claims 11
- 239000012190 activator Substances 0.000 claims 5
- 150000001875 compounds Chemical class 0.000 claims 4
- 239000000556 agonist Substances 0.000 claims 3
- 239000000841 delta opiate receptor agonist Substances 0.000 claims 3
- 200000000018 inflammatory disease Diseases 0.000 claims 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- 239000000825 pharmaceutical preparation Substances 0.000 claims 3
- 229910052736 halogen Inorganic materials 0.000 claims 2
- 150000002367 halogens Chemical class 0.000 claims 2
- YDBLKRPLXZNVNB-UHFFFAOYSA-N GW501516 Chemical group CC=1N=C(C=2C=CC(=CC=2)C(F)(F)F)SC=1CSC1=CC=C(OCC(O)=O)C(C)=C1 YDBLKRPLXZNVNB-UHFFFAOYSA-N 0.000 claims 1
- 206010061218 Inflammation Diseases 0.000 claims 1
- 102100003647 PPARA Human genes 0.000 claims 1
- 101700031509 PPARA Proteins 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 150000002148 esters Chemical class 0.000 claims 1
- 230000004054 inflammatory process Effects 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 125000000896 monocarboxylic acid group Chemical group 0.000 claims 1
- 125000003831 tetrazolyl group Chemical group 0.000 claims 1
Claims (8)
- PPARデルタ活性化因子および少なくとも1つの製剤用担体を含み、PPARデルタアゴニストが炎症性の疾病または状態の治療に使用するために有効な量で存在する、炎症の治療に使用するための医薬製剤。
- PPARデルタ活性化因子がPPARデルタアゴニストである、請求項1記載の医薬製剤。
- PPARデルタアゴニストが選択的アゴニストである、請求項2記載の医薬製剤。
- 選択的PPARデルタアゴニストがhPPARデルタ選択的アゴニストである、請求項3記載の医薬製剤。
- PPARデルタ活性化因子が、{2-メチル-4-[4-メチル-2-(4-トリフルオロメチルフェニル)チアゾール-5-イルメチルチオ]フェノキシ}酢酸である、請求項1記載の医薬製剤。
- 炎症性の疾病または状態を治療するための医薬品の製造におけるPPARデルタ活性化因子の使用。
- 化合物がPPARデルタと直接相互作用するかどうかを決定するステップ、または化合物がPPARデルタを活性化するかどうかを決定するステップを含む、炎症性の疾病または状態の治療に有用な化合物を同定する方法。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB0024361.8A GB0024361D0 (en) | 2000-10-05 | 2000-10-05 | Medicaments |
PCT/GB2001/004373 WO2002028434A2 (en) | 2000-10-05 | 2001-10-01 | Use of a ppar delta activator for treating inflammatory conditions |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2004510750A JP2004510750A (ja) | 2004-04-08 |
JP2004510750A5 true JP2004510750A5 (ja) | 2005-12-22 |
JP4106263B2 JP4106263B2 (ja) | 2008-06-25 |
Family
ID=9900709
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2002532258A Expired - Fee Related JP4106263B2 (ja) | 2000-10-05 | 2001-10-01 | 炎症性の状態の治療のためのpparデルタ活性化因子の使用 |
Country Status (9)
Country | Link |
---|---|
US (1) | US7084161B2 (ja) |
EP (1) | EP1324774B1 (ja) |
JP (1) | JP4106263B2 (ja) |
AT (1) | ATE318615T1 (ja) |
AU (1) | AU2001292046A1 (ja) |
DE (1) | DE60117584T2 (ja) |
ES (1) | ES2259675T3 (ja) |
GB (1) | GB0024361D0 (ja) |
WO (1) | WO2002028434A2 (ja) |
Families Citing this family (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2002243778A1 (en) * | 2001-02-02 | 2002-09-19 | Smithkline Beecham Corporation | Treatment of ppar mediated diseases |
WO2002100351A2 (en) * | 2001-06-11 | 2002-12-19 | Merck & Co., Inc. | A method for treating inflammatory diseases by administering a ppar-delta agonist |
EP1435946B8 (en) | 2001-09-14 | 2013-12-18 | Amgen Inc. | Linked biaryl compounds |
FR2836829B1 (fr) * | 2002-03-11 | 2005-11-25 | Bio Merieux | Utilisation de l-alpha-lysophosphatidylcholine pour obtenir la differenciation de monocytes en cellules dendritiques matures in vitro |
JP2007530703A (ja) * | 2004-04-01 | 2007-11-01 | アベンティス・ファーマスーティカルズ・インコーポレイテツド | Msおよびその他の脱髄疾患を治療するためのペルオキシソーム増殖因子活性化受容体デルタアゴニストの使用 |
EP1745003B1 (en) | 2004-05-05 | 2010-10-27 | High Point Pharmaceuticals, LLC | Novel compounds, their preparation and use |
EP1745014B1 (en) | 2004-05-05 | 2011-07-06 | High Point Pharmaceuticals, LLC | Novel compounds, their preparation and use |
WO2006020830A2 (en) | 2004-08-12 | 2006-02-23 | Amgen Inc. | Bisaryl-sulfonamides |
MX2007016374A (es) | 2005-06-30 | 2008-03-05 | Novo Nordisk As | Acidos fenoxiaceticos como activadores ppar delta. |
CN103224477A (zh) | 2005-12-22 | 2013-07-31 | 高点制药有限责任公司 | 作为PPAR-δ活化剂的苯氧基乙酸 |
EP1999098A2 (en) | 2006-03-09 | 2008-12-10 | High Point Pharmaceuticals, LLC | Compounds that modulate ppar activity, their preparation and use |
US20080004281A1 (en) * | 2006-06-28 | 2008-01-03 | Kalypsys, Inc. | Methods for the modulation of crp by the selective modulation of ppar delta |
MX2009012600A (es) * | 2007-05-21 | 2010-03-15 | Senju Pharma Co | Farmaceutico que contiene el agonista ppar alfa. |
CN102724978A (zh) * | 2009-08-14 | 2012-10-10 | 塞伦尼斯治疗公司 | 用于治疗或预防炎症或能量代谢/产生相关疾病的PPARδ配体的用途 |
KR102038866B1 (ko) * | 2012-12-24 | 2019-10-31 | 서울대학교산학협력단 | PPARδ 활성물질의 항생제, 화상 및 창상 치료제, 당뇨성 족부궤양 치료제로서의 용도 |
ES2811087T3 (es) | 2013-09-09 | 2021-03-10 | Vtv Therapeutics Llc | Uso de agonistas de PPAR-delta para tratar la atrofia muscular |
WO2023147309A1 (en) | 2022-01-25 | 2023-08-03 | Reneo Pharmaceuticals, Inc. | Use of ppar-delta agonists in the treatment of disease |
KR20230135378A (ko) * | 2022-03-16 | 2023-09-25 | 재단법인 대구경북첨단의료산업진흥재단 | 싸이아다이아졸 화합물 및 이를 포함하는 염증성 질환의 예방 또는 치료용 약학적 조성물 |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1997028149A1 (en) * | 1996-02-02 | 1997-08-07 | Merck & Co., Inc. | Method for raising hdl cholesterol levels |
CA2295930C (en) * | 1997-07-24 | 2010-12-14 | Yamanouchi Pharmaceutical Co., Ltd. | Pharmaceutical compositions having cholesterol-lowering effect |
GB9914977D0 (en) | 1999-06-25 | 1999-08-25 | Glaxo Group Ltd | Chemical compounds |
-
2000
- 2000-10-05 GB GBGB0024361.8A patent/GB0024361D0/en not_active Ceased
-
2001
- 2001-10-01 DE DE60117584T patent/DE60117584T2/de not_active Expired - Fee Related
- 2001-10-01 AT AT01972266T patent/ATE318615T1/de not_active IP Right Cessation
- 2001-10-01 JP JP2002532258A patent/JP4106263B2/ja not_active Expired - Fee Related
- 2001-10-01 WO PCT/GB2001/004373 patent/WO2002028434A2/en active IP Right Grant
- 2001-10-01 ES ES01972266T patent/ES2259675T3/es not_active Expired - Lifetime
- 2001-10-01 AU AU2001292046A patent/AU2001292046A1/en not_active Abandoned
- 2001-10-01 US US10/398,629 patent/US7084161B2/en not_active Expired - Fee Related
- 2001-10-01 EP EP01972266A patent/EP1324774B1/en not_active Expired - Lifetime
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2004510750A5 (ja) | ||
JP2004505105A5 (ja) | ||
JP2008524127A5 (ja) | ||
CN1379766A (zh) | 治疗糖尿病的苯甲酸衍生物 | |
JP2002543065A5 (ja) | ||
JP2008543854A5 (ja) | ||
JP2004535466A5 (ja) | ||
JP2002161074A5 (ja) | ||
JP2009536178A5 (ja) | ||
KR960041168A (ko) | 베타-아드레날린 효능성 작용물질 | |
JP2004516314A5 (ja) | ||
CN105189438A (zh) | 用于治疗纤维化的经取代的芳族化合物及相关方法 | |
JP2005511547A5 (ja) | ||
JP2006517939A5 (ja) | ||
JP2018135343A5 (ja) | ||
RU2007118691A (ru) | Применение 4-трифторметилфениламида (z)-2-циано-3-гидрокси-бут-2-еновой кислоты для лечения воспалительных заболеваний кишечника | |
JP2009541387A5 (ja) | ||
JP2005527576A5 (ja) | ||
JP2004510749A5 (ja) | ||
JP2015508068A5 (ja) | ||
EP1612208A3 (en) | N-phenylarylsulfonamide compound, pharmaceutical composition comprising the compound as active ingredient, synthetic intermediate for the compound and process for its preparation | |
JP2007502817A5 (ja) | ||
JP2005511516A5 (ja) | ||
JP2004532828A5 (ja) | ||
JP2004502684A5 (ja) |